These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 17275980)

  • 1. Applications of Botulinum toxin in urogynaecology.
    Sinha D; Karri K; Arunkalaivanan AS
    Eur J Obstet Gynecol Reprod Biol; 2007 Jul; 133(1):4-11. PubMed ID: 17275980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin a injection.
    Kuo HC
    Urology; 2008 Nov; 72(5):1056-60. PubMed ID: 18533231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?
    da Silva CM; Cruz F
    Curr Opin Urol; 2009 Jul; 19(4):347-52. PubMed ID: 19444121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin for detrusor overactivity and symptoms of overactive bladder: where we are now and where we are going.
    Sahai A; Khan MS; Gregson N; Smith K; Dasgupta P;
    Nat Clin Pract Urol; 2007 Jul; 4(7):379-86. PubMed ID: 17615549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial comment on: histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.
    Haferkamp A
    Eur Urol; 2008 Jun; 53(6):1253. PubMed ID: 18343561
    [No Abstract]   [Full Text] [Related]  

  • 6. [Botulinum A toxin in the treatment of patients with detrusor external sphincter dyssynergia and neurogenic low detrusor contractility].
    Mazo EB; Krivoborodov GG; Efremov NS
    Ter Arkh; 2008; 80(10):49-52. PubMed ID: 19105415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum neurotoxin type A: the poison that can treat the sick.
    Novara G
    Eur Urol; 2009 Mar; 55(3):560-2. PubMed ID: 18805630
    [No Abstract]   [Full Text] [Related]  

  • 8. Botulinum toxin for the treatment of lower urinary tract symptoms: a review.
    Sahai A; Khan M; Fowler CJ; Dasgupta P
    Neurourol Urodyn; 2005; 24(1):2-12. PubMed ID: 15578628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refractory neurogenic detrusor overactivity.
    Cruz F; Silva C
    Int J Clin Pract Suppl; 2006 Dec; (151):22-6. PubMed ID: 17169007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin treatment of urethral and bladder dysfunction.
    Chuang YC; Smith CP; Somogyi GT; Chancellor MB
    J Formos Med Assoc; 2003 Jan; 102(1):5-11. PubMed ID: 12684605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical application of Clostridium botulinum type A neurotoxin purified by a simple procedure for patients with urinary incontinence caused by refractory destrusor overactivity.
    Lee JC; Yokoyama T; Hwang HJ; Arimitsu H; Yamamoto Y; Kawasaki M; Takigawa T; Takeshi K; Nishikawa A; Kumon H; Oguma K
    FEMS Immunol Med Microbiol; 2007 Oct; 51(1):201-11. PubMed ID: 17692094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The case for bladder botulinum toxin application.
    Kim DK; Thomas CA; Smith C; Chancellor MB
    Urol Clin North Am; 2006 Nov; 33(4):503-10, ix. PubMed ID: 17011386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic detrusor overactivity.
    Schmid DM; Roy S; Sulser T; Scheiner D
    BJU Int; 2008 Jul; 102 Suppl 1():7-10. PubMed ID: 18665972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection.
    Khan S; Kessler TM; Apostolidis A; Kalsi V; Panicker J; Roosen A; Gonzales G; Haslam C; Elneil S; Fowler CJ; Dasgupta P
    J Urol; 2009 Apr; 181(4):1773-8. PubMed ID: 19233414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transperineal injection of botulinum toxin A for treatment of detrusor sphincter dyssynergia: localization with combined fluoroscopic and electromyographic guidance.
    Tsai SJ; Ying TH; Huang YH; Cheng JW; Bih LI; Lew HL
    Arch Phys Med Rehabil; 2009 May; 90(5):832-6. PubMed ID: 19406304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients' perspective of botulinum toxin-A as a long-term treatment option for neurogenic detrusor overactivity secondary to spinal cord injury.
    Hori S; Patki P; Attar KH; Ismail S; Vasconcelos JC; Shah PJ
    BJU Int; 2009 Jul; 104(2):216-20. PubMed ID: 19220255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resiniferatoxin and botulinum toxin type A for treatment of lower urinary tract symptoms.
    Cruz F; Dinis P
    Neurourol Urodyn; 2007 Oct; 26(6 Suppl):920-7. PubMed ID: 17705161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions.
    Chancellor MB; Elovic E; Esquenazi A; Naumann M; Segal KR; Schiavo G; Smith CP; Ward AB
    Toxicon; 2013 Jun; 67():129-40. PubMed ID: 23415704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity.
    Reitz A; Denys P; Fermanian C; Schurch B; Comperat E; Chartier-Kastler E
    Eur Urol; 2007 Dec; 52(6):1729-35. PubMed ID: 17884281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
    Giannantoni A; Mearini E; Del Zingaro M; Porena M
    Eur Urol; 2009 Mar; 55(3):705-11. PubMed ID: 18814955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.